Welcome to our dedicated page for EWAV news (Ticker: EWAV), a resource for investors and traders seeking the latest updates and insights on EWAV stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect EWAV's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of EWAV's position in the market.
East West Ave Acquisition Corp. (NASDAQ: EWAVU) priced its initial public offering of 10,000,000 units at $10.00 per unit, for gross proceeds of $100 million. The units are expected to begin trading on the Nasdaq Global Market under the symbol “EWAVU” on July 31, 2026.
Each unit consists of one share of common stock and one right to receive one-fourth of one share of common stock upon completion of an initial business combination. Once separately traded, the common stock and rights are expected to list on Nasdaq under “EWAV” and “EWAVR”, respectively. D. Boral Capital is acting as sole book-running manager, and underwriters have a 45-day option to purchase up to 1,500,000 additional units to cover over-allotments. The offering is expected to close on August 3, 2026, subject to customary conditions, following the SEC’s effectiveness of the Form S-1 registration statement on July 13, 2026.